The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACLARIS THERAPEUTICS INC | COM | 00461U105 | 25,908 | 1,028,084 | SH | SOLE | 0 | 1,028,084 | 0 | 0 | |
| BCLS ACQUISITION CORP | COM CL A | G0904B105 | 2,643 | 250,000 | SH | SOLE | 0 | 250,000 | 0 | 0 | |
| C4 THERAPEUTICS INC | COM STK | 12529R107 | 17,795 | 481,094 | SH | SOLE | 0 | 481,094 | 0 | 0 | |
| COGENT BIOSCIENCES INC | COM | 19240Q201 | 11,144 | 1,269,195 | SH | SOLE | 0 | 1,269,195 | 0 | 0 | |
| CELLDEX THERAPEUTICS INC NEW | COM NEW | 15117B202 | 7,621 | 369,951 | SH | SOLE | 0 | 369,951 | 0 | 0 | |
| CONSTELLATION PHARMCETICLS I | COM | 210373106 | 8,618 | 368,448 | SH | SOLE | 0 | 368,448 | 0 | 0 | |
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 13,545 | 2,983,513 | SH | SOLE | 0 | 2,983,513 | 0 | 0 | |
| DYNE THERAPEUTICS INC | COM | 26818M108 | 6,680 | 430,112 | SH | SOLE | 0 | 430,112 | 0 | 0 | |
| ESSA PHARMA INC | COM NEW | 29668H708 | 5,137 | 176,821 | SH | SOLE | 0 | 176,821 | 0 | 0 | |
| FIVE PRIME THERAPEUTICS INC | COM | 33830X104 | 13,612 | 361,344 | SH | SOLE | 0 | 361,344 | 0 | 0 | |
| GENOCEA BIOSCIENCES INC | COM NEW | 372427401 | 7,782 | 2,871,624 | SH | SOLE | 0 | 2,871,624 | 0 | 0 | |
| IVERIC BIO INC | COM | 46583P102 | 10,685 | 1,729,041 | SH | SOLE | 0 | 1,729,041 | 0 | 0 | |
| INVENTIVA SA | ADS | 46124U107 | 3,861 | 262,658 | SH | SOLE | 0 | 262,658 | 0 | 0 | |
| KALVISTA PHARMACEUTICALS INC | COM | 483497103 | 5,510 | 214,467 | SH | SOLE | 0 | 214,467 | 0 | 0 | |
| KRONOS BIO INC | COM | 50107A104 | 8,747 | 298,839 | SH | SOLE | 0 | 298,839 | 0 | 0 | |
| KURA ONCOLOGY INC | COM | 50127T109 | 14,744 | 521,555 | SH | SOLE | 0 | 521,555 | 0 | 0 | |
| LIFESCI ACQUISITION II CORP | COM | 53229E103 | 1,014 | 100,000 | SH | SOLE | 0 | 100,000 | 0 | 0 | |
| MACROGENICS INC | COM | 556099109 | 1,485 | 46,630 | SH | SOLE | 0 | 46,630 | 0 | 0 | |
| MEREO BIOPHARMA GROUP PLC | ADS | 589492107 | 6,904 | 2,048,757 | SH | SOLE | 0 | 2,048,757 | 0 | 0 | |
| MERSANA THERAPEUTICS INC | COM | 59045L106 | 6,945 | 429,228 | SH | SOLE | 0 | 429,228 | 0 | 0 | |
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 4,111 | 125,000 | SH | SOLE | 0 | 125,000 | 0 | 0 | |
| PROTAGONIST THERAPEUTICS INC | COM | 74366E102 | 9,055 | 349,600 | SH | SOLE | 0 | 349,600 | 0 | 0 | |
| RELMADA THERAPEUTICS INC | COM | 75955J402 | 5,689 | 161,565 | SH | SOLE | 0 | 161,565 | 0 | 0 | |
| SATSUMA PHARMACEUTICALS INC | COM | 80405P107 | 14,371 | 2,431,705 | SH | SOLE | 0 | 2,431,705 | 0 | 0 | |
| SERES THERAPEUTICS INC | COM | 81750R102 | 2,909 | 141,303 | SH | SOLE | 0 | 141,303 | 0 | 0 | |
| SILVERBACK THERAPEUTICS INC | COM | 82835W108 | 4,238 | 97,143 | SH | SOLE | 0 | 97,143 | 0 | 0 | |
| SYNDAX PHARMACEUTICALS INC | COM | 87164F105 | 5,288 | 236,500 | SH | SOLE | 0 | 236,500 | 0 | 0 | |
| TRILLIUM THERAPEUTICS INC | COM NEW | 89620X506 | 8,548 | 795,868 | SH | SOLE | 0 | 795,868 | 0 | 0 | |
| VIRIDIAN THERAPEUTICS INC | COM | 92790C104 | 3,104 | 185,781 | SH | SOLE | 0 | 185,781 | 0 | 0 | |
| VISTAGEN THERAPEUTICS INC | COM NEW | 92840H202 | 7,944 | 3,729,694 | SH | SOLE | 0 | 3,729,694 | 0 | 0 | |
| XENON PHARMACEUTICALS INC | COM | 98420N105 | 5,395 | 301,392 | SH | SOLE | 0 | 301,392 | 0 | 0 | |